Get the Stockscreener App
35.52
5.63%
-2.12
First Tracks Biotherapeutics Inc stock is traded at $35.52, with a volume of 495.34K.
It is down -5.63% in the last 24 hours and up +112.82% over the past month.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
See More
Previous Close:
$37.64
Open:
$37.44
24h Volume:
495.34K
Relative Volume:
0.74
Market Cap:
$1.24B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-2.72%
1M Performance:
+112.82%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$34.72
$38.18
1-Week Range:
$34.72
$42.90
52-Week Range:
$14.72
$42.90
First Tracks Biotherapeutics Inc Stock (TRAX) Company Profile
Name
First Tracks Biotherapeutics Inc
Sector
Industry
Phone
212-373-3000
Address
10770 WATERIDGE CIRCLE, SAN DIEGO
Compare TRAX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAX
First Tracks Biotherapeutics Inc
|
35.52 | 1.24B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
First Tracks Biotherapeutics Inc Stock (TRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | Leerink Partners | Outperform |
| Apr-24-26 | Initiated | Wedbush | Outperform |
| Apr-23-26 | Initiated | JP Morgan | Overweight |
| Apr-22-26 | Initiated | Barclays | Overweight |
| Apr-21-26 | Initiated | UBS | Buy |
First Tracks Biotherapeutics Inc Stock (TRAX) Latest News
Anaptysbio, Inc Net Worth (2026) - GuruFocus
Which stocks are moving before the opening bell on Thursday? - ChartMill
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
Piper Sandler Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $54 - Moomoo
TRAX Stock Hits All-Time High — What's Driving The Super Rally? - Stocktwits
First Tracks Biotherapeutics (TRAX) Stock Forum and Discussion - Moomoo
First Tracks Biotherapeutics Inc. (TRAX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
First Tracks Biotherapeutics (TRAX) News Flow - Moomoo
XPEV Stock Rises 1.5% As CEO Takes First Robotaxi Ride In Guangzhou - Stocktwits
Meta, Moderna among market cap stock movers on Friday By Investing.com - Investing.com Australia
TRAX Stock Surges As Traders Pile Into Biotech Momentum - timothysykes.com
Lithium Americas Corp. (LAC) Stock Price | Live Quotes & Charts | NYSE - timothysykes.com
Meta, Moderna among market cap stock movers on Friday - Investing.com UK
First Tracks Biotherapeutics price target raised to $44 from $30 at H.C. Wainwright - TipRanks
Aehr Test Systems, Lam Research, Applied Materials And Other Big Stocks Moving Higher On Thursday - Sahm
TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart - mexc.co
J.P. Morgan Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT - RTTNews
H.C. Wainwright Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $44 - Moomoo
Wells Fargo Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Barclays Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Market Movers | Winners: FBRX, TRAX, CIRC | Losers: BYRN, RXT, AEON - Trefis
TRAX Stock Explodes Higher As Traders Pile Into Momentum - timothysykes.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Forte, First Tracks soar on CD122 success in vitiligo; celiac next - BioWorld News
H.C. Wainwright reiterates First Tracks stock Buy rating at $30 By Investing.com - Investing.com Canada
TRAX Reiterated by First Tracks -- Price Target Maintained at $3 - GuruFocus
Is AnaptysBio’s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus? - simplywall.st
First Tracks Biotherapeutics, Inc.(NasdaqGS:TRAX) added to Russell Microcap Value Benchmark Index - marketscreener.com
First Tracks Biotherapeutics, Inc.(NasdaqGS:TRAX) added to Russell 2000 Value Benchmark - marketscreener.com
First Tracks Biotherapeutics, Inc.(NasdaqGS:TRAX) added to Russell 2500 Value Benchmark - marketscreener.com
TRAX Forecast — Price Target — Prediction for 2027 - TradingView
The Nasdaq Biotechnology Index closed up more than 1.52%. Among its constituents, Absci surged 35.96%, Silence Therapeutics rose 26.00%, and Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies gai - Bitget
AnaptysBio Subleases San Diego Facility to First Tracks - The Globe and Mail
First Tracks Biotherapeutics (NASDAQ: TRAX) subleases 45,057 sq ft in San Diego - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
TRAX SEC FilingsFirst Tracks Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
First Tracks Biotherapeutics Ord Shs (TRAX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rita Jain of First Tracks Biotherapeutics (TRAX) exercises RSUs, lifts holdings to 19,194 shares - Stock Titan
First Tracks Biotherapeutics (TRAX) director settles 6,030 RSUs into shares - Stock Titan
[Form 4] First Tracks Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
First Tracks Biotherapeutics (TRAX) director converts 6,030 RSUs into common shares - Stock Titan
Magda Marquet at First Tracks Biotherapeutics (TRAX) settles 6,030 RSUs - Stock Titan
First Tracks Biotherapeutics (TRAX) director converts 6,030 RSUs into common stock - Stock Titan
First Tracks Biotherapeutics Inc Stock (TRAX) Financials Data
There is no financial data for First Tracks Biotherapeutics Inc (TRAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
First Tracks Biotherapeutics Inc Stock (TRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schmid John P. | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
37,652 |
| Orwin John A | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
16,695 |
| Ware J. Anthony | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
15,660 |
| Marquet Magda | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
15,960 |
| FENTON DENNIS M | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
10,995 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):